ResMed Inc. Announces Record Financial Results for the Quarter Ended Septembe...(: Cash and cash equivalents ...),Health

Date:11/5/2009

: Cash and cash equivalents $477,824 $415,650 Accounts receivable, net 208,825 212,096 Inventories 175,108 157,431 Deferred income taxes 43,859 44,368 Income taxes receivable 4,998 2,067 Prepaid expenses and other current assets 29,196 21,672 ----------------------------------------- ------ ------ Total current assets 939,810 853,284 -------------------- ------- ------- Property, plant and equipment, net 397,375 377,613 Goodwill 221,186 213,169 Other intangibles 35,431 35,023 Deferred Income taxes 20,464 19,364 Other assets 5,870 9,515 ------------ ----- ----- Total non-current assets 680,326 654,684 ------------------------ ------- ------- Total assets $1,620,136 $1,507,968 ------------ ---------- ---------- Liabilities and Stockholders' Equity Current liabilities: Accounts payable $47,287 $48,293 Accrued expenses 75,297 67,018 Deferred revenue 31,192 28,881 Income taxes payable 69,808 56,972 Deferred Income taxes 416 391 Current portion of long-term debt 68,296 67,545 --------------------------------- ------ ------ Total current liabilities 292,296 269,100 -----------
'/>"/>

SOURCE ResMed Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
6. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
9. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF